Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Adoptive immunotherapy using CTL has provided some clinical benefit to patients with metastatic melanoma. Use of cloned CTL of known specificity might improve clinical effect, but technical difficulties have limited exploration of this possibility. We have used fluorescence-driven cell sorting to clone tumor-specific CTL after staining with tetrameric MHC class I/peptide complexes. CTL specific for the melanoma Ags melan-A, tyrosinase, and MAGE3 were cloned from the peripheral blood, tumor-infiltrated lymph nodes, and skin metastases of five patients. Clones were isolated and characterized in as little as 6 weeks, much faster than is possible with previous techniques. We show that these CTL clones express markers compatible with immunotherapeutic use in melanoma, including the cutaneous lymphocyte Ag, which is associated with homing to skin.

Type

Journal article

Journal

J Immunol

Publication Date

15/06/1999

Volume

162

Pages

6959 - 6962

Keywords

Adult, Aged, Antigens, Neoplasm, Clone Cells, Epitopes, T-Lymphocyte, Female, HLA-A2 Antigen, Humans, Immunotherapy, Adoptive, Male, Melanoma, Middle Aged, Neoplasm Proteins, Oligopeptides, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured